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Summary: Cortical spreading depression (CSD) is a tempo-
rary disruption of local ionic homeostasis that propagates
slowly across the cerebral cortex. Cortical spreading depression
promotes lesion progression in experimental stroke, and may
contribute to the initiation of migraine attacks. The purpose of
this study was to investigate the roles of the marked increase of
nitric oxide (NO) formation that occurs with CSD. Microdialy-
sis electrodes were implanted in the cortex of anesthetized rats
to perform the following operations within the same region: (1)
elicitation of CSD by perfusion of high K+ medium; (2) re-
cording of CSD elicitation; (3) application of the NO synthase
inhibitor, NG-nitro-L-arginine methyl ester (L-NAME); and (4)
recording of dialysate pH changes. The primary effect of L-
NAME (0.3 to 3.0 mmol/L in the perfusion medium) was a
marked widening of individual CSD wave, resulting essentially
from a delayed initiation of the repolarization phase. This
change was due to NO synthase inhibition because it was not
observed with the inactive isomer D-NAME, and was reversed
by L-arginine. This effect did not appear to be linked to the
suppression of a sustained, NO-mediated vascular change as-
sociated with the superposition of NO synthase inhibition on
high levels of extracellular K+. The delayed initiation of repo-
larization with local NO synthase inhibition may reflect the
suppression of NO-mediated negative feedback mechanisms
acting on neuronal or glial processes involved in CSD genesis.
However, the possible abrogation of a very brief, NO-mediated
vascular change associated with the early phase of CSD cannot
be ruled out. Key Words: Spreading depression—Nitric ox-
ide—Nitric oxide synthase—L-NAME—Migraine—Stroke—
N-methyl-D-aspartate.
Cortical spreading depression (CSD) is a transient
suppression of electrical activity, resulting from a tem-
porary disruption of local brain ionic homeostasis that
propagates slowly across the cerebral cortex (Bureš et
al., 1974; Martins-Ferreira et al., 2000). Experimental
and clinical data suggest that CSD may be the underlying
cause of migraine attacks, even when they are not pre-
ceded by aura symptoms (Cao et al., 1999; Lauritzen,
1994). Stroke is another neurologic disorder that may
involve CSD, because recurrent periinfarct CSD pro-
motes lesion progression in experimental models of focal
ischemia (Hossmann, 1996; Obrenovitch, 1995).
Increased nitric oxide (NO) formation is likely to oc-
cur during CSD because NMDA-receptor antagonists
suppress CSD (Marrannes et al., 1988; Obrenovitch and
Zilkha, 1996), intracellular Ca2+ levels increase mark-
edly during CSD (Hansen and Zeuthen, 1981), and
NMDA-receptor activation leads to a large increase in
Ca2+/calmodulin-dependent nitric oxide synthase (NOS)
activity (Garthwaite and Boulton, 1995). A CSD-induced
NO release was confirmed by real-time measurements of
NO in the cortex of anesthetized cats, which showed a
rapid and sustained increase of NO levels for the dura-
tion of K+-induced CSD activity (Read et al., 1997; Read
and Parsons, 1998).
One possible role of NO release during CSD may be
regional CBF (rCBF) coupling to increased energy de-
mand (Faraci and Brian, 1994), the latter of which is a
well-established feature of CSD (Silver and Erecinska,
1994). Several studies using laser Doppler flowmetry
were dedicated to this issue, but whether NO mediates
the early increase in rCBF that is associated with CSD is
still controversial (Duckrow, 1993; Fabricius et al., 1995;
Read and Parsons, 1998; Wolf et al., 1996; Zhang et al.,
1994). These discrepancies may be due to differences in
experimental design, particularly regarding doses of
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NOS inhibitors, but also to limitations of laser Doppler
flowmetry (Fabricius and Lauritzen, 1996; Soehle et al.,
2001).
Another possible role of NO release during CSD may
be rapid feedback inhibition of processes that are in-
volved in CSD genesis (e.g., ion channels, glutamate
release), thereby contributing to minimize the duration of
this potentially deleterious event. This is a plausible hy-
pothesis because NO is very diffusible, the NO–cyclic
GMP pathway is capable of subsecond operations (Bel-
lamy and Garthwaite, 2001), and NMDA-receptors
would be likely candidates because there is robust evi-
dence for negative feedback of NMDA-receptors by en-
dogenous NO (Manzoni and Bockaert, 1993; Moller et
al., 1995; Tanaka et al., 1993).
The purpose of this study was to investigate the role(s)
of NO release during CSD using an innovative experi-
mental strategy that relied on (1) selective application of
the NOS inhibitor L-NAME to the site of CSD elicita-
tion; (2) comprehensive, quantitative analysis of both
individual and repeated CSD; and (3) analysis of the
recovery from acidosis to evaluate the possible involve-
ment of NO-mediated vascular effects. We show that
local NOS inhibition delays markedly the initiation of
recovery from individual CSD wave. This effect does not
appear to be a consequence of the suppression of any
local, NO-mediated hyperperfusion associated with CSD.
MATERIALS AND METHODS
Animal preparation and intracerebral microdialysis
Experiments were performed on adult, male Sprague Dawley
rats (weight [mean ± SD], 312 ± 27 g, n 45; Harlan UK Ltd,
Bicester, U.K.) with food and water available ad libitum. They
were housed in the animal unit of our institution for at least 1
week before use. All animal procedures complied with the
British Home Office guidelines, Animals (Scientific Procedure)
Act of 1986. All efforts were made to minimize the number of
animals used and their suffering. Animals were anesthetized
throughout with halothane (5% for induction, 2.0% to 2.5%
during surgery, and 1.5% to 1.75% for maintenance during the
rest of the experiment) in 30:70 oxygen to nitrous oxide mix-
ture while the animal breathed spontaneously. Concentric mi-
crodialysis probes incorporating a recording electrode (Obre-
novitch et al., 1993; AN69 Hospal membrane, 0.25-mm outer
diameter × 1-mm fiber length; type ME-H1, Applied Neuro-
science Ltd., London, U.K.) were implanted in the frontopari-
etal cortex (coordinates: 1.3 to 1.5 mm anterior to bregma, 2
mm lateral, and 1.4 to 1.5 mm deep from the cortical surface)
(Paxinos and Watson, 1986) and held in place with acrylic
dental cement embedding two small stainless-steel skull screws
used as anchor. Unless otherwise stated, microdialysis probes
were perfused with aCSF (composition in millimoles per liter:
125 sodium chloride, 2.5 potassium chloride, 1.18 magnesium
chloride, and 1.26 calcium chloride; pH 7.3 adjusted with
1-mol/L sodium hydroxide) at 1 L/min with a syringe pump
(CMA/100; CMA/Microdialysis, Solna, Sweden). These mul-
tifunctional devices allowed the following operations to be car-
ried out simultaneously, within the same region of the cerebral
cortex (Fig. 1): (1) reproducible elicitation of CSD by switch-
ing from normal aCSF to a medium containing 160-mmol/L K+
(K-medium); (2) recording of the extracellular DC potential to
detect CSD initiation precisely at the site of its elicitation; (3)
local application of the NOS inhibitor, L-NAME (alone or with
L-arginine) or its inactive isomer D-NAME; and (4) recording
of dialysate pH changes in one series. Restricting NOS inhibi-
tion to the site of CSD elicitation ruled out any possible inter-
ference from peripheral NOS inhibition. Indeed, drug-induced
changes in arterial blood pressure could have altered the mag-
nitude of hyperperfusion associated with K+-induced increase
in brain energy demand, thereby influencing acid–base homeo-
stasis (Taylor et al., 1994), and acidosis is known to inhibit both
NMDA-receptor function (Traynelis and Cull-Candy, 1990;
Urenjak et al., 1997) and CSD (Gardner-Medwin, 1981; Mar-
rannes et al., 1985).
A femoral artery was catheterized for continuous monitoring
of arterial blood pressure, and a vein for rapid induction of
cardiac arrest on completion of the experimental procedure. To
minimize any possible interference of halothane anesthesia
with the processes under study (Carla and Moroni, 1992;
Schlame and Hemmings, 1995), once the surgical procedure
had been completed, the depth of anesthesia was carefully con-
trolled by monitoring the EEG and arterial blood pressure, and
the concentration of halothane in the breathing mixture kept to
a minimum (1.5% to 1.75%). It is relevant to note that halo-
thane did not interfere with neuronal NOS-mediated control of
CBF in a previous study (Zagvazdin et al., 1998). Body tem-
perature was maintained at 37.0°C throughout the experiment.
Recording of extracellular DC potential
and electroencephalogram
These electrophysiologic variables were derived from the
potential between the electrode built into the microdialysis
probe and a silver/silver chloride reference electrode placed
under the scalp (Obrenovitch et al., 1993). This signal was first
amplified with a high-impedance input, AC/DC preamplifier
(NL834 or NL102; Neurolog System, Digitimer Ltd., Welwyn
Garden City, U.K.). The alternating current component in the 1
to 30 Hz window (×5000–10000 overall amplification) pro-
vided the EEG, and the DC component (×250 overall amplifi-
cation) the DC potential. All the recorded variables were con-
tinuously digitized, displayed, and stored using a personal
computer equipped with an A/D converter. Cortical spreading
depression is recognized as a transient, negative shift of the
extracellular DC potential, superimposed on the sustained shift
FIG. 1. Illustration of the experimental strategy relying on the use
of microdialysis probes incorporating an electrode for elicitation
of cortical spreading depression (CSD), recording of CSD, local
application of nitric oxide synthase inhibitor, and monitoring pH
changes in the emerging dialysate.
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resulting from the imposed high extracellular K+ concentration
(Fig. 2).
Recording of changes in dialysate pH
The CSD-induced pH changes in the dialysate were recorded
as it emerged from the outlet of the implanted microdialysis
probe (Fig. 1), by using a micro pH-sensor and separate refer-
ence electrode (MINI-Flex NMPH2 and Flex-ref, respectively;
World Precision Instruments Ltd., Stevenage, U.K.). The sen-
sitive tip of the pH electrode was inserted within the lumen of
the probe outlet tube, and the reference positioned laterally in
such a way that suitable contact with the emerging fluid was
maintained throughout the recording period (Fig. 1). The po-
tential difference between these two electrodes was amplified
(×250 overall amplification; NL106 and NL530, Neurolog Sys-
tem, Digitimer Ltd.), digitized, and acquired together with the
other variables for off-line analysis. The sensitivity of the pH
sensor was linear within the pH range of 6.7 to 7.3, with a slope
of approximately 24 mV per pH unit. The time response of the
pH sensor was rapid (seconds) and, therefore, the limiting fac-
tor regarding time resolution of changes in dialysate pH was the
microdialysis process.
Experimental procedures
Experiments were performed at least 2 hours after probe
implantation. Cortical spreading depressions were triggered by
switching the perfusion medium from normal aCSF to K-
medium (composition in millimoles per liter: 2.5 sodium chlo-
ride, 160 K+, 1.18 magnesium chloride, and 1.26 calcium chlo-
ride; pH 7.3 adjusted with 1-mol/L sodium hydroxide) using a
liquid switch (CMA/110, CMA/Microdialysis AB). Previous
studies showed that such a high concentration of K+ is required
to evoke consistent, periodic CSD under these experimental
conditions (Herreras and Somjen, 1993; Obrenovitch and
Zilkha, 1996; Szerb, 1991), possibly because of the efficient
uptake of K+ by brain cells (Chen and Nicholson, 2000; Xiong
and Stringer, 2000) and because a minimum volume of tissue
(approximately 1 mm3) has to be depolarized for successful
CSD elicitation (Koroleva and Bureš, 1996). Each K+ stimulus
was followed by 40 minutes of recovery (i.e., perfusion of a
normal K+ concentration medium). Three series of experiments
were performed.
Series 1. Three groups were considered in this series (con-
trol, L-NAME, D-NAME), with a single microdialysis electrode
implanted in each animal. Five episodes of repetitive CSD
where produced by perfusion of K-medium for 20 minutes. L-
or D-NAME (dissolved in aCSF and K-medium) was applied at
the concentration of 0.3, 1, and 3 mmol/L during the second,
third, and fourth CSD episode (in respective order), with 60
minutes of drug application started 20 minutes before the cor-
responding perfusion of K-medium.
Series 2. The purpose of this series was to determine whether
the effects of NOS inhibition on CSD could be reversed by
L-arginine, and to examine whether the same effects could be
obtained without application of L-NAME before CSD initia-
tion. Accordingly, L-NAME (with or without L-arginine) was
only coapplied with K+ in these experiments. Because series 1
showed that the primary effect of L-NAME was a marked al-
teration of individual CSD, only a single CSD wave was trig-
gered per K+ application (i.e. K-medium was perfused for 5
minutes only). To reduce the number of animals required, two
microdialysis electrodes were implanted symmetrically in each
animal of a single group. Five separate CSD were elicited on
each side. During the second, third, and fourth CSD elicitation
period, the K-medium was supplemented with 1-mmol/L L-
NAME on one side, and with 1-mmol/L L-NAME plus L-
arginine (10, 3, and 1 mmol/L, respectively) on the other. The
range of L-arginine concentrations tested was reversed (i.e.,
highest concentration applied first) because L-NAME has a
much higher affinity for NOS than L-arginine (Alderton et al.,
2001) and series 1 showed that the effects of L-NAME on CSD
persisted for more than 40 minutes (Fig. 3). Cortical spreading
depression was not elicited simultaneously at each probe be-
cause we had observed in pilot experiments that CSD on one
side of the cortex provoked a small negative shift of the con-
tralateral DC potential. Therefore, one CSD was produced on
one side, and 20 minutes within the following recovery period,
CSD was then elicited contralaterally.
Series 3. The aim of this series was to help to determine
whether the effects of NOS inhibition on CSD, identified
through series 1 and 2, could result from the suppression of any
local, NO-mediated vascular change induced by CSD. Two
groups were considered (control and L-NAME), with implan-
tation of a single microdialysis electrode because we did not
have the necessary equipment for dual pH monitoring. Five
separate, individual CSD were elicited, each by perfusion of
K-medium for approximately 5 min. In these experiments, per-
fusion of K-medium was interrupted as soon as CSD was elic-
ited, to standardize the state of the CSD plus K challenge when
recovery was initiated, and thereby the period during which
dialysates pH normalization was studied (see Data presentation
and analysis). In the control group, standard K-medium was
used throughout for CSD elicitation. In the L-NAME group, 1
mmol/L of the drug was added to the K-medium used to trigger
the second, third, and fourth CSD wave.
Drugs
Both L-NAME and D-NAME were purchased from Tocris
Cookson Ltd. (Bristol, U.K.), and L-arginine was purchased
from Sigma Chemicals (Poole, U.K.). All other chemicals were
of analytical grade. Drug solutions were prepared on the day of
the experiment, and ultimately dissolved in aCSF or K-medium
with pH adjusted to 7.3.
Estimation of the microdialysis probe delivery ratios
In vitro experiments were performed to evaluate the percent-
age of L-NAME and L-arginine delivered through the probe.
FIG. 2. Representative changes in the DC potential produced by
perfusion of high K+-medium through a microdialysis probe, and
set of variables used for quantitative determination of the cortex
sensitivity to K+-induced cortical spreading depression (CSD;
main trace): number of CSD (N); cumulative CSD area (shaded
area; in millivolts per minute); and latency for occurrence of first
CSD (L, in minutes). The insert to the right shows the variables
used to analyze drug effects on individual CSD waves: CSD
height (H, in millivolts); width at 1/2 height (W, in seconds); maxi-
mum slope of depolarization (Sld, in millivolts per minute); and
maximum slope of repolarization (Slr, in milllivolts per minute).
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Microdialysis probes identical to those used in vivo were per-
fused with L-NAME (1 mmol/L) or L-arginine (10 mmol/L) at
1 L/min, and immersed in normal aCSF maintained at 37.0°C.
The remaining concentration of each compound in the dialysate
was measured in three consecutive 20-minute dialysate samples
by ultraviolet detection (270 and 202 nm for L-NAME and
L-arginine, respectively), and the delivery ratio (%) was calcu-
lated as
Perfused drug concentration
− Dialysate drug concentration
Perfused drug concentration × 100
Data presentation and analysis
As in previous studies (Obrenovitch and Zilkha, 1996; Ure-
njak and Obrenovitch, 2000), drug effects on the cortex sus-
ceptibility to repeated CSD elicited by K+ (series 1) were as-
sessed through the analysis of changes in the following
variables (Fig. 2): number of CSD elicited (N), cumulative
CSD area (A, in millivolts × minute), and latency for occur-
rence of first CSD (L, in minutes). Because NOS inhibition
altered the pattern of individual CSD waves, the following
variables were also examined (Fig. 2): CSD height (H, in mil-
livolts), width at 1/2 CSD height (W, in seconds), and maxi-
mum slope of depolarization (Sld, in millivolts per minute) and
repolarization (Slr, in millivolts per minute). For series 1, this
second set of variables was considered only for the first CSD of
each K-medium application to avoid any possible interference
from previous CSD within the same K stimulus. Comprehen-
sive in vitro evaluation of the pH sensor under our experimental
conditions revealed an interference of large changes in the K+-
concentration of the solution tested (i.e., switch from aCSF to
K-medium produced a steady shift in the recording potential of
0.78 mV, equivalent to a change of approximately 0.03 pH
units). In addition, the time resolution of the microdialysis/pH-
sensor combination could not resolve any possible change spe-
cific to CSD alone. Therefore, the quantitative analysis of the
pH signal in series 3 was restricted to the recovery phase, and
consisted in the determination of the rate of recovery from
acidosis resulting from the combined CSD/K challenge, when
any interference of high K+ with the pH recording could be
ruled out (Fig. 6, bottom trace). All values in Results are means
± SD. The Student’s t-test was used for statistical analysis,
and a probability less than 5% was considered statistically
significant.
RESULTS
The delivery ratio was 37.7 ± 5.6% (n  7) for L-
NAME (i.e., the extracellular concentration achieved
with 1 mmol/L of the drug in the perfusion medium was
estimated to be approximately 0.4 mmol/L). A similar
delivery ratio was found for L-arginine (32.9 ± 4.2%,
n  7).
Series 1
In the control group, the first 20-minute perfusion of
160-mmol/L K+ elicited 6.2 ± 1.2 CSD waves, with a
corresponding cumulative CSD area of 23.2 ± 5.1
mV/min, and 1.6 ± 0.4 minutes as first CSD latency. As
in previous studies based on the same experimental pro-
tocol (Obrenovitch and Zilkha, 1996; Urenjak and Obre-
novitch, 2000), the subsequent K+ stimuli were progres-
sively less effective in triggering CSD, as shown by the
reduced number of CSD elicited, reduced cumulative
area, and prolonged latency (Fig. 3, bar charts). L-NAME
reduced significantly the number of CSD, but this change
was not associated with any prolongation of first CSD
latency and, paradoxically, the cumulative CSD area was
markedly increased (Fig. 3). These sets of changes sug-
gested strongly that the primary effect of local NOS in-
hibition was a marked “widening” of individual CSD
(Fig. 3, L-NAME trace). In contrast, only the highest
concentration of D-NAME tested (i.e., 3 mmol/L) altered
CSD, reducing slightly (but significantly) both the num-
ber of CSD and corresponding area (Fig. 3, bar charts).
In the control group (n  6), and for the first CSD
elicited by the first K+ stimulus, the peak height and
width (at 1⁄2 peak) were 11.7 ± 2.4 mV and 26.1 ± 4.0
seconds, respectively. There was no change in these vari-
ables with the successive K+ in control and D-NAME
groups (see Fig. 4 for CSD width, data not shown for
height). L-NAME increased slightly the height of the first
CSD, but this change was only significant with the
FIG. 3. Effects of local nitric oxide synthase inhibition with L-
NAME on repetitive cortical spreading depression (CSD) in the
cerebral cortex of rats, and comparison with the inactive isomer
D-NAME (series 1). Five separate episodes of repetitive CSD
were produced by perfusion of 160-mmol/L K+ for 20 minutes
through a microdialysis probe/electrode. In the L-NAME and D-
NAME groups, 0.3, 1.0, and 3.0 mmol/L of the drug was coper-
fused with high K+ during the second, third, and fourth challenge,
respectively. The left traces are representative changes of the
DC potential recorded with the third K+ stimulus. In agreement
with previous reports, the polarity of the DC potential was re-
versed so that negative shifts (i.e., depolarization) produce an
upward deflection. Values are means ± SD in the bar charts. Note
the marked increase in the cumulative CSD area under nitric
oxide synthase inhibition (L-NAME), and that this effect persisted
when L-NAME was omitted from the last K+ stimulus. *P < 0.05,
**P < 0.01, ***P < 0.001, comparison of the L- and D-NAME groups;
†P < 0.05, ††P < 0.01, comparison of the D-NAME and control
groups; Student’s t-test (n = 6–8).
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3-mmol/L concentration (9.0 ± 0.9 and 10.3 ± 1.3 mV for
D- and L-NAME groups, respectively; P < 0.05, n  7
and 8). The most striking change with NOS inhibition
was a marked, concentration-dependent increase in CSD
width (Fig. 4). This effect was consistent within each
K+-stimulus (Fig. 3, L-NAME trace), very significant
throughout the range or L-NAME concentration tested,
and it persisted when L-NAME was omitted for the last
challenge (Fig. 4, bar chart).
To determine whether this effect involved a change in
the rate of depolarization (Sld) and/or repolarization (Slr),
these two variables were determined for the first CSD of
the third K+-stimulus (i.e., test of 1-mmol/L L-NAME
and D-NAME). Sld was 43.6 ± 11.8, 50.4 ± 9.3 and 43.3
± 9.8 mV/min in the control, L-NAME, and D-NAME
group, respectively (n 6–9). The slight increase of Sld
with L-NAME was not significant. Slr was 34.6 ± 1.7,
28.4 ± 5.6 and 39.1 ± 6.3 mV/min in the control, L-
NAME, and D-NAME group, respectively. Slr was sig-
nificantly reduced by 1-mmol/L L-NAME (i.e., repolar-
ization was slower; P < 0.01, comparison between
D-NAME and L-NAME, n  7 and 9). Therefore, a
slower recovery of the DC-potential negative shift in-
dicative of CSD did contribute to the increased width of
CSD under NOS-inhibition, but the major contributor
was actually a delay in the initiation of the repolarization
phase (Fig. 7).
Series 2
On the L-NAME side, the width (at 1⁄2 peak) of the first
CSD (i.e., K-medium without any drug) was 24.2 ± 3.7
seconds (n  9). This variable was consistently and
significantly increased in all the subsequent CSD (Fig.
5), and this change was very similar qualitatively and
quantitatively to that observed in series 1 (Fig. 4). This
effect was reversed significantly by L-arginine at all the
concentrations tested (Fig. 5). These data confirm that
the effect of L-NAME on CSD was due to effective NOS
inhibition in the cell populations surrounding the micro-
dialysis fiber. These findings also show that this is
readily achieved when L-NAME is added to the perfu-
sion medium, because L-NAME was not applied before
the K+ stimuli in these experiments. However, note on
the L-NAME side that the drug effect on CSD width was
less marked with the first drug application than with the
subsequent ones (Fig. 5, bar chart).
Series 3
In the L-NAME group, the width (at 1⁄2 peak) of the
first CSD (i.e., K-medium without any drug) was 24.6 ±
3.5 seconds (n 8), and this variable increased signifi-
cantly with all the subsequent challenges (Fig. 6). In
agreement with series 2 data (1-mmol/L L-NAME with-
out L-arginine), the magnitude of the increase obtained
with the second K+ challenge (i.e., first CSD with
FIG. 4. Effects of local nitric oxide synthase (NOS) inhibition with
L-NAME on the pattern of the first individual cortical spreading
depression (CSD) elicited by the high extracellular K+ concentra-
tions (series 1; see Fig. 3 legend for methodologic details). The
left traces are representative recordings of the first CSD wave
obtained with the third K+ stimulus. Values are means ± SD in the
bar chart. Note the marked increase in the width of individual
CSD under NOS inhibition (L-NAME), with this effect persisting
when L-NAME was omitted from the last K+ stimulus. ***P < 0.001,
comparison of the L- and D-NAME groups; Student’s t-test (n = 7
and 8).
FIG. 5. Effect of local nitric oxide synthase (NOS) inhibition with
L-NAME on individual K+-induced cortical spreading depression
(CSD; series 2), and its reversal with L-arginine. Five single CSD
were elicited, each by 5-minute perfusion of 160-mmol/L K+ with
40 minutes of subsequent recovery (i.e., perfusion of aCSF). On
the L-NAME side, 1 mmol/L of the drug was dissolved in the
K-medium for the second, third, and fourth challenge (no pre-
treatment and posttreatment in this series). On the contralateral
side (+L-Arg), L-arginine was coapplied with L-NAME, with the
highest concentration of L-arginine applied first (10, 3, and 1
mmol/L) because series 1 showed that the effects of L-NAME
persisted for more than 40 minutes (Figs. 3 and 4). The left traces
are representative CSD recorded with the third K+ stimulus. Val-
ues are means ± SD in the bar charts. *P < 0.05, comparison of
the L-NAME and L-NAME plus L-arginine sides (n = 9 and 7);
Student’s t-test.
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1-mmol/L L-NAME) was one half that observed with the
subsequent CSD, also with 1 mmol/L L-NAME; how-
ever, the effect of L-NAME persisted at the fifth K+
challenge when the drug was no longer present (Figs. 5
and 6, CSD width bar charts). Regarding pH recovery
(Fig. 6, lower trace and bar chart), the average SlRpH for
the first CSD plus K challenge in the control group was
0.47 ± 0.13 mV/min (n  9), approximately 0.02 pH
units/min), and there was no significant change at any
time between the control and L-NAME groups.
DISCUSSION
Local nitric oxide synthase inhibition and cortical
spreading depression: primary effect
In series 1, L-NAME reduced significantly the fre-
quency of repetitive CSD during 20-minute perfusion of
K-medium, but this effect did not reflect inhibition
of CSD elicitation because the first CSD latency was not
prolonged (Fig. 3). Measures of cumulative CSD area
and individual CSD waves showed that the primary
effect of L-NAME was a marked widening of each CSD
(i.e., increased CSD duration), resulting essentially from
a delayed initiation of the repolarization phase (Figs. 4, 5
and 7). This action of L-NAME was effectively due to
NOS inhibition, because it was not observed with D-
NAME and was reversed by L-arginine (Figs. 3–5). The
reduced CSD frequency under L-NAME was presumably
a consequence of this primary effect, through a prolon-
gation of the refractory period. Indeed, each CSD is fol-
lowed by a refractory period during which the elicitation
of subsequent CSD is inhibited (Brand et al. 1998), and
the refractory period is likely to be prolonged by longer-
lasting CSD as a result of more pronounced disruption of
cellular ionic homeostasis and metabolism (Koroleva
and Bureš 1980, 1996). When the same concentration of
L-NAME (1 mmol/L) was coapplied with several con-
secutive K+-challenges (series 2 and 3), the drug effect
was consistently less with the first K challenge. This also
occurred when L-NAME was applied 20 minutes before
CSD elicitation (Wang M, Urenjak J, Obrenovitch TP,
unpublished data, 2001). In other terms, the full effect of
the concentration of L-NAME tested on CSD required its
application in association with a previous CSD, thus sug-
gesting activation-dependent inhibition of NOS or the
presence of preformed pools of NO-containing factors
(Davisson et al., 1996).
Comparison of the effects of L-NAME on cortical
spreading depression with those of 7-nitroindazole
In a previous study with the purported in vivo neuronal
selective NOS inhibitor 7-nitroindazole (Moore and
Handy 1997; Reiner and Zagvazdin, 1998; Alderton et
al., 2001), very different effects were observed (Urenjak
and Obrenovitch, 2000). First, perfusion of 1-mmol/L
7-nitroindazole through the probe produced a small but
detectable negative shift of the DC potential, which was
not observed with L-NAME. Second, 7-nitroindazole in-
hibited significantly CSD elicitation as indicated by re-
duced frequency, decreased cumulative CSD area, and
increased first CSD latency. These changes were not re-
versed by L-arginine. One possible origin for these dif-
ferent effects is the monoamine oxidase B-inhibitory ac-
tion of 7-nitroindazole, which was not found with
L-NAME (Desvignes et al., 1999; Di Monte et al., 1997),
because CSD implies synchronous neurotransmitter re-
lease, including that of dopamine (Moghaddam et al.,
1987), and the dopamine-receptor D2 agonist, Quin-
pirole inhibited spreading depression in the retina model
(de Azeredo and Ribeiro, 1992). One common action of
7-nitroindazole and L-NAME was the widening of CSD,
but it was much smaller with 1-mmol/L 7-nitroindazole
(1.2-fold vs. twofold with 1-mmol/L L-NAME in this
study). This difference in magnitude may be linked to the
different potency of these two NOS inhibitors; 7-
FIG. 6. Effects of local nitric oxide synthase (NOS) inhibition with
1-mmol/L L-NAME on cortical spreading depression (CSD) width
(upper bar chart), and rate of pH recovery (SlRpH) from the CSD
plus K-application challenge (lower bar chart) observed in series
3. Five single CSD were elicited by perfusion of 160-mmol/L K+,
with each subsequent 40 minutes of recovery (i.e., perfusion of
aCSF) initiated as soon as CSD elicitation was detected. In the
L-NAME group, 1 mmol/L of the drug was dissolved in the K-
medium for the second, third, and fourth challenge (i.e. no pre-
CSD and post-CSD drug treatment in this series). The left traces
are representative recordings of the DC potential (upper trace)
and pH changes (lower trace) during CSD and K-application. The
latter shows the data sequence used for computation of the rate
of pH recovery (SlRpH). In agreement with previous reports, the
polarity of the DC potential was reversed so that negative shifts
(i.e., depolarization) produce an upward deflection. In the pH
trace, an upward trend of the signal indicates an acidification of
the dialysate; the regular oscillations of the pH signal were due to
cyclic irregularities in the rate of perfusion of the “high-precision”
syringe pump. Values are means ± SD in the bar charts (n = 7–9).
***P < 0.001, comparison of the L-NAME and control groups
with Student’s t-test. Comparisons within the L-NAME group
(paired t-test): aP < 0.001, comparison of the second versus the
first CSD (i.e., first CSD with L-NAME to CSD without drug, re-
spectively); bP < 0.01, comparison of the second versus the third
CSD (i.e., first and second CSD with coapplication of L-NAME,
respectively).
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nitroindazole is approximately 30-times less potent than
L-NAME (Alderton et al., 2001).
Delayed initiation of repolarization during nitric
oxide synthase inhibition: direct neuronal or
indirect vascular origin?
It is likely that perfusion of L-NAME through the mi-
crodialysis probe resulted in an equivalent inhibition of
both neuronal and endothelial NOS in the surrounding
cell populations because in vitro tests showed that the
IC50 for L-NAME inhibition of NOS is approximately
0.3 mol/L for both isoforms (Alderton et al., 2001). In
addition, in the brain tissue, NO formation subsequent to
activation of either endothelial or neuronal NOS can con-
tribute to the coupling of rCBF to metabolism (Ayata et
al., 1996; Wiencken and Casagrande, 1999), and CSD
does imply increased energy demand with associated hy-
perperfusion (Lauritzen, 1994). Therefore, the delayed
initiation of repolarization demonstrated during NOS in-
hibition could reflect either a direct action at neuronal
level (e.g., suppression of NO-mediated negative feed-
back control of processes involved in CSD) or an indirect
action at vascular level (i.e., suppression of NO-mediated
hyperperfusion associated with CSD, with secondary ef-
fect on CSD recovery). Two elements are especially rel-
evant when considering the possibility of a vascular ori-
gin: (1) the precise kinetic of rCBF changes in relation to
CSD; and (2) the role of NO in the coupling of rCBF to
CSD. The point-by-point analysis provided next is cen-
tered on these two elements.
• Studies of rCBF changes with laser Doppler flowme-
try showed that the blood flow response to CSD con-
sisted essentially in a sharp increase in rCBF, lasting
around 2 minutes in untreated cortex, and starting well
within the repolarization phase (Gold et al., 1998;
Hashimoto et al., 2000). This finding suggests that the
hyperperfusion (even if NO mediated) actually oc-
curred after the primary effect of NOS inhibition on
CSD that we observed (i.e., delayed initiation of re-
polarization; Figs. 4, 5 and 7).
• When the hyperperfusion subsequent to CSD was
markedly attenuated by the serotonin 2A/2C receptor
antagonist ritanserin (Gold et al., 1998), the DC-
potential recovery was significantly prolonged, appar-
ently because of a slower rate of recovery. When NOS
was inhibited locally in our study, the rate of recovery
of the DC potential was also slower, but the primary
contributor to wider CSD was a delayed initiation of
repolarization (Fig. 7).
• Four studies from different laboratories showed that
administration of NOS inhibitors in rats did not alter
the marked hyperperfusion that is associated with
CSD, despite independent measures proving that brain
NOS activity was effectively inhibited (Fabricius et
al., 1995; Read and Parsons, 1998; Wolf et al., 1996;
Zhang et al., 1994). In two studies, NOS inhibition
revealed or enhanced a brief initial hypoperfusion that
preceded CSD (Duckrow, 1993; Fabricius et al.,
1995), suggesting that an initial vasoconstrictor com-
ponent may be present as CSD is elicited. Only in one
study did NOS inhibition reduce the hyperperfusion
associated with CSD (Duckrow, 1993). Overall, there
is little evidence supporting the notion that NO is the
primary mediator of hyperemia induced by CSD in
rats.
Delayed initiation of repolarization during nitric
oxide synthase inhibition: a consequence of altered
energy status in the brain region under study?
Using a 3 × 6-mm perfused cortical window in anes-
thetized rats, Dreier et al. (1998, 2001) have observed
that superimposition of high K+ (35 mmol/L) on NOS
inhibition (1-mmol/L NG-nitro-L-arginine) produced
clear signs of imbalance between local energy demand
and blood supply that were similar to those observed
with ischemia. Therefore, one could speculate that the
altered CSD waves observed under NOS inhibition were
a consequence of their elicitation in an energy-
compromised region (i.e., the cellular population sur-
rounding the implanted microdialysis probe/electrode).
The following elements observed during NOS inhibition
do not support this hypothesis: (1) the latency for CSD
elicitation was not prolonged, in contrast to what would
be expected from a region with disrupted cellular ionic
homeostasis and metabolism (Koroleva and Bureš, 1980,
1996); (2) a much slower rate of repolarization should
have been observed, especially when K+ application and
NOS inhibitor were applied for 20 and 60 minutes, re-
spectively (series 1; Fig. 7, left diagram); (3) there was
no detectable change in the rate of recovery from acido-
sis (Fig. 6); (4) the rate of early repolarization after
switching from K-medium to aCSF was not altered by
FIG. 7. Diagrams of changes in the pattern of individual cortical
spreading depression (CSD) wave produced by 1-mmol/L L-
NAME, which show that the major contributor to wider CSD under
nitric oxide synthase inhibition was a marked delay in the initia-
tion of the repolarization phase. These diagrams were con-
structed from the averaged CSD height, width at 1⁄2 height, and
maximum rates of depolarization and repolarization, computed
for the third K+ challenge in the control (dashed lines) and L-
NAME group (solid lines) in series 1 and 3.
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L-NAME, even when the drug application persisted
within the recovery period (series 1; data not shown); (5)
a comprehensive examination of the recorded EEG sig-
nals (series 1; control and L-NAME experiments) did not
reveal any sign of ischemia when L-NAME was super-
imposed on 160-mmol/L K+, and there was no signifi-
cant difference in the rate of EEG recovery from indi-
vidual CSD wave (203 ± 48 and 185 ± 119%/min in the
control and L-NAME group, respectively). It is likely
that, in our study, ischemia was not produced because of
the very small region that was exposed to the combina-
tion of high K+ concentration and NOS inhibition.
From this analysis of our and previously published
data, we speculate that the delayed initiation of repolar-
ization, observed when CSD was elicited under local
NOS inhibition, reflected the suppression of NO-
mediated negative feedback mechanism(s) controlling
the duration of CSD. By matching the mechanisms in-
volved in CSD with possibilities for NO-mediated modu-
lation, three different molecular targets can be identified
for such a negative feedback: (1) NMDA-receptors (Choi
and Lipton, 2000), though ongoing experiments do not
support this hypothesis (Urenjak J, Wang M, Obreno-
vitch TP, unpublished data, 2001); (2) glutamate exocy-
tosis (Sistiaga et al., 1997); and (3) gap junctions, which
are necessary for the propagation of CSD (Nedergaard et
al., 1995) and can be modulated by NO (O’Donnell and
Grace, 1997; Rorig and Sutor, 1996).
An alternative explanation for the effect of L-NAME
that we observed, which cannot be ruled out by the data
presented herein, is the suppression by L-NAME of a
very brief, NO-mediated vasodilation associated with the
early phase of CSD, such as that reported by Duckrow
(1993) and Fabricius et al. (1995). Should such a tran-
sient NO-mediated vasodilation and its impact on the
initiation of repolarization be confirmed, than an impor-
tant role of NO-mediated vasodilatation in the brain may
be to respond rapidly to changes in neuronal activity
and/or depolarization before other less responsive cere-
brovascular control mechanisms.
Selective pharmacologic and genetic manipulations
have shown that the pathogenesis of neuronal ischemic
injury can be altered by NO, either positively or nega-
tively, depending on the stage of evolution of ischemic
injury and on the cellular source of NO (Dawson and
Dawson, 1998; Iadecola, 1997; Shimizu-Sasamata et al.,
1998). The current consensus is that NO produced by
endothelial NOS is beneficial by favoring blood supply
to vulnerable regions (e.g., the penumbra), whereas post-
ischemic production of NO by neuronal NOS may be
neurotoxic. Our finding that NO production associated
with CSD promotes the initiation of the recovery phase
from this potentially deleterious event adds a new degree
of complexity to this already complicated picture.
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